ENGINEERING MEDICINES TO IMPROVE PATIENT CARE Investors News Releases Year None20232022202120202019201820172016 November 21, 2023 Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference November 13, 2023 Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 8, 2023 Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference November 3, 2023 Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology October 30, 2023 Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing October 26, 2023 Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease September 25, 2023 Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors September 7, 2023 Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September August 8, 2023 Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 4, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last » Displaying 1 - 10 of 32
Year None20232022202120202019201820172016 November 21, 2023 Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference November 13, 2023 Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 8, 2023 Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference November 3, 2023 Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology October 30, 2023 Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing October 26, 2023 Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease September 25, 2023 Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors September 7, 2023 Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September August 8, 2023 Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 4, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last » Displaying 1 - 10 of 32
November 21, 2023 Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
November 13, 2023 Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 3, 2023 Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology
October 30, 2023 Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing
October 26, 2023 Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease
September 7, 2023 Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September
August 8, 2023 Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 4, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)